| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
22 |
| Employees |
56 |
| Revenues (TTM) (Millions $) |
21 |
| Net Income (TTM) (Millions $) |
-44 |
| Cash Flow (TTM) (Millions $) |
-35 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
F Star Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of cancer immunotherapy drugs. They specialize in developing novel bispecific antibodies, which are designed to target two different binding sites on cancer cells to activate the immune system to attack them. The company is headquartered in Cambridge, Massachusetts, USA, and has operations in the UK and the Netherlands.
The company was founded in 2006 by a team of biologists and biochemists, with a vision to create a new class of cancer therapeutics that harness the power of the immune system in fighting the disease. Their proprietary technology platform is built around the use of bispecific antibodies, which are engineered to bind to specific antigens on tumor cells, as well as activating immune cells, such as T-cells, to target and destroy them.
The company has a pipeline of over ten bispecific antibody candidates that are designed to target a range of cancers, including solid tumors, hematologic cancers, and rare cancers. Their lead product candidate, FS118, is a promising first-in-class bispecific antibody that targets both B7-H3 and CD3, two antigens that are commonly overexpressed on cancer cells. The drug is currently in Phase 1 clinical trials for the treatment of advanced solid tumors, and early results look promising.
F-Star is also working closely with other leading biotech companies and academic institutions, such as Merck KGaA and MD Anderson Cancer Center, to develop new candidate drugs that could be used in combination therapies for a range of cancers. Their research collaborations are focused on finding new ways to improve cancer immunotherapy, by developing new approaches to activate and recruit immune cells to the tumor microenvironment.
The company has a highly experienced and talented team of scientists and executives, who have a deep understanding of cancer biology and immunotherapy. They are highly committed to developing innovative new therapeutics that can make a difference in the lives of cancer patients around the world. With a strong pipeline and growing research collaborations, F-star Therapeutics looks poised to become a major player in the cancer immunotherapy space.
Company Address: Eddeva B920 Babraham Research Campus Cambridge 0
Company Phone Number: 1223-497400 Stock Exchange / Ticker: NASDAQ FSTX
|
%